Rovanersen - WaVe life Sciences
Alternative Names: BMTR5150; WV-1092; WVE-120101Latest Information Update: 02 Oct 2021
At a glance
- Originator WaVe life Sciences
- Class Antisense oligonucleotides; Neuroprotectants
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Huntington's disease
Most Recent Events
- 22 Jun 2021 Wave Life Sciences terminates a phase I/II trial for Huntington's disease in Canada, Poland, United Kingdom, France, Australia, Germany, Denmark and USA (Intrathecal) (NCT03225833)
- 16 Jun 2021 Wave Life Sciences terminates a phase I/II trial in Huntington's disease in Australia, Canada, France, Poland, Denmark, Germany and United Kingdom (NCT04617847)
- 06 Apr 2021 Asuragen has been acquired by Bio-Techne